Avicanna (AVCN) investor relations material

Company overview and business model

• Focused on evidence-based, standardized cannabinoid-based products for medical and pharmaceutical use, not recreational markets.

• Four commercial divisions: medical cannabis products, medical cannabis platform (MyMedi), pharmaceutical pipeline, and raw material/API division in Colombia.

• RHO Phyto is the flagship medical brand, offering non-inhaled, targeted cannabinoid products for specific clinical indications.

• MyMedi.ca, acquired from Shoppers Drug Mart, is a nationwide online pharmacy/telemedicine platform providing patient support, treatment planning, and insurance adjudication.

• The company operates internationally under federal legislation, exporting to over 20 countries and focusing on medical and pharmaceutical applications.

Research, development, and intellectual property

• Extensive R&D history, including collaborations with leading academic and clinical institutions in Canada.

• Owns significant intellectual property, including several USPTO patents and numerous pipeline products submitted for patent approval.

• Developed proprietary drug delivery technologies, such as nano-emulsion, now commercialized in multiple products.

• Clinical data and real-world evidence from MyMedi platform inform product development and support patent filings.

• Intellectual property and translational research provide a sustainable competitive advantage and attract global partners.

Pharmaceutical pipeline and clinical progress

• Four major drug candidates targeting sleep, rare skin diseases, pain management, anxiety/depression, and epilepsy.

• Trunerox, the first approved pharmaceutical, launched in Colombia for Lennox-Gastaut Syndrome, with plans for expansion in South America.

• Ongoing phase II clinical trial for osteoarthritic pain at Toronto General Hospital/UHN, with data and IP retained by the company.

• Two advanced topical candidates for rare skin diseases and local inflammatory pain, leveraging insights from medical cannabis platform.

• Plans to collaborate with mid-to-large pharma companies for late-stage clinical development and out-licensing.